GyneFix IUD Plus LNG-IUS for Adenomyosis
NCT: NCT07680985 · COMPLETED
Brief Summary
Adenomyosis is a common gynecological condition that can cause menstrual pain, heavy menstrual bleeding, anemia, and reduced quality of life. The levonorgestrel-releasing intrauterine system is commonly used as a conservative treatment, but displacement or expulsion of the device may occur, especially in patients with an enlarged uterus or a deep uterine cavity. This study evaluated whether combining an Indomethacin-GyneFix intrauterine device with a levonorgestrel-releasing intrauterine system could improve device stability in patients with adenomyosis. Eligible participants were randomly assigned to receive GyneFix IUD plus LNG-IUS, ring IUD plus LNG-IUS, or LNG-IUS alone. Participants were followed for 6 months after device placement. The main outcome was device displacement or expulsion at 6 months. Other outcomes included menstrual pain, menstrual blood loss, uterine volume, hemoglobin, CA125, adverse events, and treatment acceptance.
Frequently Asked Questions
What is GyneFix IUD Plus LNG-IUS for Adenomyosis?
GyneFix IUD Plus LNG-IUS for Adenomyosis is a clinical trial registered under NCT07680985. Current status: COMPLETED.
What is the status of NCT07680985?
The current status of NCT07680985 (GyneFix IUD Plus LNG-IUS for Adenomyosis) is: COMPLETED.
When did GyneFix IUD Plus LNG-IUS for Adenomyosis start?
GyneFix IUD Plus LNG-IUS for Adenomyosis started on 2023-07-20.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.